Reliability note

Titles and AI summaries are unofficial English monitoring aids, not legal advice or official translations. Each link opens the original Japanese official source, which remains authoritative.

Notice amendment on reporting suspected adverse reactions after routine and temporary vaccinations

「定期の予防接種等による副反応疑いの報告等の取扱いについて」の一部改正について」を掲載しました

Published: 2026-11-16 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · First detected by this dashboard: 2026-11-17

View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard

AI summary

Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.

Summary

The official page explains that physicians and other reporting professionals must report specified symptoms following routine or temporary vaccinations to the Ministry of Health, Labour and Welfare under Article 12(1) of the Immunization Act; duplicate reporting under the pharmaceuticals and medical devices legislation is unnecessary. The supplied PDF lists symptom-onset intervals, including four hours for anaphylaxis, four months for suppurative lymphadenitis following BCG vaccination, and 30 minutes for vasovagal reactions involving fainting; these are not filing deadlines. PMDA announced on 2026-11-16 the posting of a partial amendment to the notice on handling suspected adverse-reaction reports following routine and temporary vaccinations, and the page lists a related notice dated 2026-11-13. The excerpts do not identify the specific amendments or establish an effective date.

Business Impact

Physicians and other healthcare reporting professionals, including pharmacy, hospital and clinic operators, dentists and pharmacists, may need to distinguish reporting arrangements for routine or temporary vaccinations from those for voluntary vaccinations. Vaccine marketing authorization holders may receive report information excluding patient names other than initials and dates of birth, and may request follow-up cooperation from reporters.

Recommended Action

A review could compare the 2026-11-13 notice with its predecessor to identify the actual changes and any implementation date, and check the symptom-onset criteria against the reporting form instructions.